MDxHealth SA
ISIN: BE0003844611 | Ticker: MDXH | LEI: 549300J3MG9F9B5FY646
Country: Belgium
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on proprietary genetic, epigenetic and other complex molecular technologies.
Mdxhealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers.
2003
Served areaWorldwide
HeadquartersCAP Business Center Rue d'Abhooz 31, 4040 Herstal, Liège – Belgium
| Line item in (usd) | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 31,856,000.00 | N/A | 75,072,000.00 | 119,135,000.00 |
| Noncurrent Assets | N/A | 8,765,000.00 | N/A | 8,466,000.00 | 89,986,000.00 |
| Property Plant And Equipment | N/A | 973,000.00 | N/A | 1,671,000.00 | 3,791,000.00 |
| Goodwill | N/A | N/A | N/A | 0.00 | 35,926,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 5,058,000.00 | N/A | 3,448,000.00 | 46,166,000.00 |
| Current Assets | N/A | 23,091,000.00 | N/A | 66,606,000.00 | 29,149,000.00 |
| Cash and cash equivalents | 22,050,000.00 | 15,953,000.00 | 15,953,000.00 | 58,498,000.00 | 15,503,000.00 |
| Other Current Assets | N/A | 1,043,000.00 | N/A | 1,615,000.00 | 1,962,000.00 |
| Equity And Liabilities | N/A | 31,856,000.00 | N/A | 75,072,000.00 | 119,135,000.00 |
| Equity | 19,724,000.00 | 5,849,000.00 | 5,849,000.00 | 46,899,000.00 | 9,315,000.00 |
| Issued Capital | N/A | 76,716,000.00 | N/A | 128,454,000.00 | 133,454,000.00 |
| Retained Earnings | N/A | -215,300,000.00 | N/A | -244,302,000.00 | -288,346,000.00 |
| Share Premium | N/A | 136,349,000.00 | N/A | 153,177,000.00 | 153,177,000.00 |
| Reserve Of Sharebased Payments | N/A | 9,385,000.00 | N/A | 10,607,000.00 | 11,474,000.00 |
| Liabilities | N/A | 26,007,000.00 | N/A | 28,173,000.00 | 109,820,000.00 |
| Noncurrent Liabilities | N/A | 12,986,000.00 | N/A | 11,741,000.00 | 91,542,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 690,000.00 | N/A | 1,466,000.00 | 53,537,000.00 |
| Longterm Borrowings | N/A | 10,279,000.00 | N/A | 7,651,000.00 | 34,914,000.00 |
| Current Liabilities | N/A | 13,021,000.00 | N/A | 16,432,000.00 | 18,278,000.00 |
| Other Current Financial Liabilities | N/A | 909,000.00 | N/A | 961,000.00 | 2,327,000.00 |
| Other Current Liabilities | N/A | 3,217,000.00 | N/A | 2,735,000.00 | 3,985,000.00 |
| Line item in (usd) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 18,460,000.00 | 22,239,000.00 | 37,054,000.00 |
| Revenue From Rendering Of Services | 18,064,000.00 | 21,937,000.00 | 36,965,000.00 |
| Revenue From Royalties | 146,000.00 | 52,000.00 | 64,000.00 |
| Licence Fee Income | 250,000.00 | 250,000.00 | 25,000.00 |
| Profit Loss From Operating Activities | -27,123,000.00 | -26,841,000.00 | -37,900,000.00 |
| Finance Income | 4,000.00 | 11,000.00 | N/A |
| Finance Costs | 1,543,000.00 | 2,161,000.00 | 6,144,000.00 |
| Profit Loss Before Tax | -28,662,000.00 | -29,002,000.00 | -44,044,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -28,662,000.00 | -29,002,000.00 | -44,044,000.00 |
| Line item in (usd) | 01.01.2021 | 02.01.2020 | 01.01.2022 | 02.01.2021 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | -28,662,000.00 | N/A | -29,002,000.00 | N/A | -44,044,000.00 |
| Adjustments For Decrease Increase In Inventories | -1,132,000.00 | N/A | 413,000.00 | N/A | -416,000.00 |
| Adjustments For Depreciation And Amortisation Expense | 3,332,000.00 | N/A | 3,036,000.00 | N/A | 4,909,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 273,000.00 | N/A | 0.00 | N/A | 44,000.00 |
| Adjustments For Sharebased Payments | 1,295,000.00 | N/A | 1,222,000.00 | N/A | 867,000.00 |
| Other Adjustments For Noncash Items | 26,000.00 | N/A | -325,000.00 | N/A | -473,000.00 |
| Cash Flows From Used In Operating Activities | -20,244,000.00 | N/A | -22,548,000.00 | N/A | -34,118,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | N/A | 0.00 | N/A | 25,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 537,000.00 | N/A | 896,000.00 | N/A | 2,789,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | N/A | 0.00 | N/A | 1,374,000.00 |
| Interest Received Classified As Investing Activities | 0.00 | N/A | 11,000.00 | N/A | N/A |
| Cash Flows From Used In Investing Activities | -537,000.00 | N/A | -896,000.00 | N/A | -29,163,000.00 |
| Proceeds From Issuing Shares | 13,875,000.00 | N/A | 68,566,000.00 | N/A | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | 2,316,000.00 | N/A | 0.00 | N/A | 34,291,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | N/A | 0.00 | N/A | 10,805,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 831,000.00 | N/A | 1,057,000.00 | N/A | 1,358,000.00 |
| Interest Paid Classified As Financing Activities | 1,070,000.00 | N/A | 1,011,000.00 | N/A | 1,412,000.00 |
| Cash Flows From Used In Financing Activities | 14,290,000.00 | N/A | 66,509,000.00 | N/A | 20,841,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -6,491,000.00 | N/A | 43,065,000.00 | N/A | -42,440,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 394,000.00 | N/A | -520,000.00 | N/A | -555,000.00 |
| Cash and cash equivalents | 15,953,000.00 | 22,050,000.00 | 58,498,000.00 | 15,953,000.00 | 15,503,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 11.09.23 | KALFUS RON | Executive member | Buy | EUR 116,000.00 |
| 10.09.23 | Sollee Joseph | Executive member | Buy | EUR 58,000.00 |
| 26.09.22 | KALFUS RON | Executive member | Buy | EUR 136,800.00 |
| 23.09.22 | Sollee Joseph | Executive member | Buy | EUR 136,800.00 |
| 26.01.21 | SLAGMULDER REGINE | Board | Buy | EUR 79,653.00 |
| 25.01.21 | SLAGMULDER REGINE | Board | Buy | EUR 216,298.00 |
| 21.09.20 | SLAGMULDER REGINE | Board | Buy | EUR 37,824.80 |
| 18.09.20 | SLAGMULDER REGINE | Board | Buy | EUR 7,223.00 |
| 17.09.20 | SLAGMULDER REGINE | Board | Buy | EUR 2,860.40 |
| 16.09.20 | SLAGMULDER REGINE | Board | Buy | EUR 4,988.20 |
BE0003844611
LEI549300J3MG9F9B5FY646
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.